SEC Company Response from Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — Oct 25, 2018
Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: Oct. 25, 2018 · CIK: 0001659617 · Accession: 0001144204-18-055247
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227845
Letter
Re: Moleculin Biotech, Inc.
October 25,
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Registration Statement on Form S-1
Registration No. 333-227845
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on October 26, 2018, or as soon thereafter as possible on such date.
Very truly yours,
Moleculin Biotech, Inc.
Show Raw Text
CORRESP
1
filename1.htm
October 25,
2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Re: Moleculin Biotech, Inc.
Registration Statement on Form
S-1
Registration No. 333-227845
Ladies and Gentlemen:
Pursuant to Rule 461
of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby
respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be
declared effective at 4:30 P.M. (Eastern Time) on October 26, 2018, or as soon thereafter as possible on such date.
Very truly yours,
Moleculin Biotech, Inc.
By:
/s/ Jonathan Foster
Name: Jonathan Foster
Title: Chief Financial Officer